tbuckley/cabot-search huggingface dataset:
Vigilancia de las salmonelosis humanas en Bulgaria, 1999-2004 : evoluci¨®n, cambios y resistencia a los antibi¨®ticos
Authors: G Asseva, P Petrov, I Ivanov, T Kantardjiev
Journal: Eurosurveillance (2006)

Este art¨aculo estudia la distribuci¨®n de salmonelas resistentes y de los mecanismos de resistencia entre los serotipos m¨¢s frecuentes en Bulgaria. Su identificaci¨®n se realiz¨® por cultivos, pruebas bioqu¨amicas y serotipado : test de difusi¨®n en disco Bauer-Kirby para el estudio de la resistencia a 14 antibi¨®ticos ; test de sinergia en doble disco para la b¨²squeda de cepas productoras de ¦Â-lactamasas de amplio espectro (extended¨Cspectrum ¦Â-lactamases, ESBL) ; transferencia de los genes codificadores para ESBL por conjugaci¨®n experimental. Se utilizaron bla-CTX-M, bla-SHV y bla¨CTEM para la detecci¨®n por reacci¨®n en cadena de la polimerasa (PCR). Doscientas cuarenta y cinco cepas de salmonella resistentes se identificaron de esa manera. La mayor¨aa de ellas proced¨aan de casos humanos espor¨¢dicos o de infecciones asintom¨¢ticas, y solo 23 cepas se hab¨aan aislado de brotes. Se detectaron 79 cepas productoras de ESBL: Cinco S. Enteritidis, una S. Typhimurium, nueve S. Isangi y 62 S. Corvallis produciendo los enzimas CTX-M3, TEM y SHV. Los genes codificadores para ESBL se transfirieron con ¨¦xito a una cepa de E. coli C1A con los genes codificadores para la resistencia a los aminogluc¨®sidos y al cloranfenicol (para bla-SHV y bla-TEM). La amplificaci¨®n por PCR revel¨® la presencia de genes bla-CTX- M3 en la cepa S. Enteritidis, y de genes bla-SHV y bla-TEM en S. Corvallis. Las salmonelas presentan una resistencia creciente a todas las clases de antimicrobianos importantes para los tratamientos. Bulgaria es el primer pa¨as en el mundo donde se detectaron cepas de S. Corvallis BLSE. 
Se identific¨® una gran variedad de genes de resistencia entre los serotipos de salmonella m¨¢s frecuentemente asociados con enfermedades humanas en Bulgaria.
PATH-37. THE NATURAL COURSE OF HYPERMUTATOR GLIOMAS
Authors: Carlos Kamiya-Matsuoka, Kenna Shaw, Monica Loghin, Marta Penas-Prado, Barbara J O’Brien, Shiao-Pei Weathers, Kristin Alfaro-Munoz, W K Alfred Yung, John de Groot
Journal: Neuro-Oncology (2017)

Hypermutator genotype (HMGen) is seen in glioblastoma (GBM) and lower-grade gliomas (LLG). It may be induced by and related to resistance to alkylating agents. We describe demographics, mutational features, treatment and outcome of HMGen gliomas. Retrospective review at MD Anderson between 02/2006-02/2017 identified 314 glioma patients (171 GBM), with tissue analyzed by next-generation sequencing. HMGen was defined as tumors harboring 30 or more mutations, or displaying mutations in mismatch repair (MMR) or DNA polymerase (pol) genes. 39 (12%) patients had HMGen. 26 (67%) were men. 19 (48.7%) had at least 30 mutations, 11 (28.2%) had mutations in pol gene, 6 (15.4%) in MMR, 1 had mutations in both genes, and only 2 met all criteria. GBM (N=26, 67%) was the most common tumor (N=5, 19% IDH1-mutated), followed by WHO grade III oligodendroglioma (N=8, 20%) and astrocytoma (N=3, 7.7%). Most frequent HMGen were pol gene mutation (N=10, 38%) and high mutational burden (N=8, 87%). For WHO grade II, 1 oligodendroglioma showed MMR mutation and 1 astrocytoma had 30 mutations. HMGen was found as initial genotype in 17 (65%) GBMs (N=14, IDH-wild-type), the rest after treatment with alkylating agents. Mean temozolomide cumulative dose in GBM was 24 grams, 21 grams in WHO grade III astrocytomas and 43 grams in WHO grade III oligodendrogliomas. Only 2 patients received lomustine (0.7 and 0.5 g) and 1 cyclophosphamide (5.5 g). Time from initial diagnosis-to-HMGen was 42 and 70 months, diagnosis-to-last follow-up 27 and 95 months, and OS 68 and 74 months for GBM and LGG, respectively. HMGen commonly presented after treatment with alkylating agents, with lower dosing in the astrocytic lineage. GBM with HMGen may occur spontaneously and may be associated with longer survival than historical controls. Further investigation is needed to determine whether HMGen can be predicted due to its important clinical implications.
ANGI-13. DEXAMETHASONE-MEDIATED INHIBITION OF GLIOBLASTOMA NEUROSPHERE DISPERSAL IN AN EX VIVO ORGANOTYPIC NEURAL ASSAY
Authors: Ahmed Meleis, Aria Mahtabfar, Ramsey Foty
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is a highly aggressive tumor. Early dispersal of the primary tumor renders localized therapy ineffective. Recurrence always occurs and ultimately leads to patient death. Prior studies have described how the dispersive nature of GBM can be significantly reduced through Dexamethasone-mediated reactivation of fibronectin matrix assembly, and reorganization of cortical actin into stress fibers. However, prior analyses examined GBM dispersal on tissue culture plastic, or polystyrene filters seeded with normal human astrocytes, which differ from the parenchymal architecture of neuronal tissue. The aim of this study was to develop a reliable ex-vivo model to examine cellular migration from GBM neurospheres on multiple substrates including mouse retina, and slices of mouse, pig, and human brain. Dispersal was measured by plating untreated or Dex-treated fluorescently labeled neurospheres onto isolated mouse retinas, or 100 micron-thick slices of pig, mouse or human brain. Dex-doses ranged from 1x10-6M to 1x10-8M. After 24 hours of incubation, images were captured and quantified in ImageJ. Two-way ANOVA was performed to examine the effects of Dex treatment and type of neural tissue on neurosphere dispersal. Dose-response curves were generated, analyzed by global nonlinear regression and LogEC50 were compared by Extra Sum-of-Squares F-test. The effects of both Dex treatment and tissue type were found to be extremely significant (p<0.0001), as was the interaction between the two variables (p<0.001). Tukey’s HSD test showed that Dex treatment significantly reduced dispersal on each type of neuronal tissue compared to the untreated group (p<0.05). Log EC50 values indicate that it is possible to achieve 50% reduction in dispersal, with doses ranging from 3-30-fold lower than those used to control edema. A unique ex-vivo, qualitative assay was developed, showing significant Dex-mediated inhibition of GBM cells from 3D spheroids on various neuronal tissues including mouse retina/brain, human brain and pig brain.
P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
Authors: N. Karachaliou, M. González Cao, A. Giménez-Capitán, A. Drozdowskyj, E. Aldeguer, C. Teixido, G. Crespo, M. Molina-Vila, S. Viteri, M. De Los Llanos Gil, S. Martín Algarra, E. Pérez-Ruiz, I. Márquez-Rodas, D. Rodríguez-Abreu, R. Blanco, T. Puértolas, M.A. Royo, R. Rosell
Journal: Journal of Thoracic Oncology (2017)
ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: Martin van den Bent, Analia Azaro, Filip Vos, Juan Sepulveda, W K Alfred Yung, Patrick Wen, Andrew Lassman, Markus Joerger, Ghazaleh Tabatabai, Jordi Rodon, Ralph Tiedt, Sylvia Zhao, Tiina Kirsilae, Sergio Vicente, Andrea Myers, Wolfgang Wick
Journal: Neuro-Oncology (2017)

c-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small molecule inhibitor of c-MET; BKM120 is a pan-class I PI3K inhibitor. A phase Ib/II study was designed to evaluate INC280+BKM120 in patients with recurrent GBM (NCT01870726). Key objectives were to estimate the MTD/RP2D of INC280+BKM120 and to characterize safety/tolerability, pharmacokinetics (PK), and anti-tumor activity of INC280+BKM120 and INC280 alone. Key eligibility criteria were: age ≥ 18 years; ECOG PS ≤ 2, and recurrent GBM (RANO criteria) following ≤ 2 prior systemic therapies, including VEGF inhibitors. For inclusion in phase Ib, mutation/homozygous deletion of PTEN, a suppressor of PI3K signals, was required (irrespective of c-MET status). For phase II with INC280 alone, c-MET amplification (GCN > 5) was required. Blood and tumor specimens were collected for PK and molecular analyses. Thirty-three patients were enrolled in six phase Ib dose cohorts of INC280+BKM120. DLTs were nausea, personality change, and elevated transaminases. MTD was identified at INC280 300 mg BID + BKM120 80 mg QD. RP2D was not declared due to: poor tolerability; a drug-drug interaction resulting in low BKM120 exposure; and no strong evidence of activity. The INC280+BKM120 phase II arm was not opened. In the INC280 monotherapy arm, 10 patients (median age 48 years; 70% women, 90% Caucasian) were enrolled. The most common INC280-related AEs (all grades) were nausea and fatigue. Three patients had stable disease as best response (RANO). Molecular analyses are ongoing. The MTD of INC280 300 mg BID + BKM120 80 mg QD was identified, with both doses below the single agent RP2Ds. Limited efficacy was observed with the combination in PTEN altered GBM. INC280 alone was well-tolerated but displayed no clear evidence of anti-tumor activity in heavily pre-treated GBM with c-MET alteration.
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
Authors: Noelle K. LoConte, Abenaa M. Brewster, Judith S. Kaur, Janette K. Merrill, Anthony J. Alberg
Journal: Journal of Clinical Oncology (2017)

Alcohol drinking is an established risk factor for several malignancies, and it is a potentially modifiable risk factor for cancer. The Cancer Prevention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stance by the Society to minimize excessive exposure to alcohol has important implications for cancer prevention. In addition, the role of alcohol drinking on outcomes in patients with cancer is in its formative stages, and ASCO can play a key role by generating a research agenda. Also, ASCO could provide needed leadership in the cancer community on this issue. In the issuance of this statement, ASCO joins a growing number of international organizations by establishing a platform to support effective public health strategies in this area. The goals of this statement are to: • Promote public education about the risks between alcohol abuse and certain types of cancer; • Support policy efforts to reduce the risk of cancer through evidence-based strategies that prevent excessive use of alcohol; • Provide education to oncology providers about the influence of excessive alcohol use and cancer risks and treatment complications, including clarification of conflicting evidence; and • Identify areas of needed research regarding the relationship between alcohol use and cancer risk and outcomes.
P3.09-003 Heart Radiation Dose as a Risk Factor for Dyspnea Worsening After Multimodality Treatment for NSCLC and MPM: An Exploratory Analysis
Authors: A. Botticella, C. Billiet, G. Defraene, S. Peeters, C. Draulans, P. Nafteux, K. Nackaerts, C. Deroose, D. De Ruysscher
Journal: Journal of Thoracic Oncology (2017)
Gastroenteritis outbreaks on cruise ships: contributing factors and thresholds for early outbreak detection
Authors: Varvara A Mouchtouri, Eleni Verykouki, Dumitru Zamfir, Christos Hadjipetris, Hannah C Lewis, Christos Hadjichristodoulou
Journal: Eurosurveillance (2017)

When an increased number of acute gastroenteritis (AG) cases is detected among tourists staying at the same accommodation, outbreak management plans must be activated in a timely manner to prevent large outbreaks. Syndromic surveillance data collected between 1 January 2010 and 31 December 2013 by five seagoing cruise ships were analysed to identify attack rate thresholds for early outbreak detection. The overall incidence rate of AG was 2.81 cases per 10,000 traveller-days (95% confidence interval (CI): 0.00-17.60), while the attack rate was 19.37 cases per 10,000 travellers (95% CI: 0.00-127.69). The probability of an outbreak occurring was 11% if 4 per 1,000 passengers reported symptoms within the first 2 days of the voyage, and this increased to 23 % if 5 per 1,000 passengers reported such within the first 3 days. The risk ratio (RR) for outbreak occurrence was 2.35, 5.66 and 8.63 for 1, 2 and 3 days' delay of symptoms reporting respectively, suggesting a dose-response relationship. Shipping companies' policies and health authorities' efforts may consider these thresholds for initiating outbreak response measures based on the number of cases according to day of cruise. Efforts should focus on ensuring travellers report symptoms immediately and comply with isolation measures.
STEM-19. THE TCF12 TRANSCRIPTION FACTOR CONTROLS PRONEURAL GLIOBLASTOMA STEM-LIKE CELLS
Authors: Rukayat Taiwo, Diane Mao, Tatenda Mahlokozera, Albert Kim
Journal: Neuro-Oncology (2017)

The basic helix-loop-helix (bHLH) transcription factor, TCF12, has been implicated in precursor cell proliferation during embryogenic neurogenesis and continues to be expressed postnatally in mitotically active regions of the brain. TCF12 has been shown to be preferentially expressed in glioblastoma stem-like cells (GSCs), a key subpopulation of cancer cells thought to underlie tumor therapy resistance and recurrence. But the exact role of TCF12 in gliomagenesis has remained unclear since it has been shown to be both a proto-oncogene and tumor suppressor depending on the cellular context. We therefore investigated the potential role of TCF12 in regulating the biology of GSCs. Using microarray analysis of 24 patient-derived GSCs, we find that TCF12 is highly expressed in proneural GSCs relative to normal human astrocytes, and differentiation of proneural GSCs in culture markedly downregulated TCF12 mRNA. To test the role of TCF12 in GSC function, we first overexpressed TCF12 in GSCs using a lentiviral approach. TCF12 overexpression increased GSC self-renewal capacity, a key measure of stem-like cell identity, relative to control infection. Mechanistically, a mini-screen of candidates known to regulate GSC self-renewal revealed that TCF12 overexpression increased the expression of the bHLH transcription factor, OLIG2 and the helix-loop-helix protein, ID-1. Furthermore, loss-of-function approaches using both RNA interference and CRISPR-Cas9-mediated knockout demonstrated reduced expression of OLIG2 and ID1. Bioinformatic analysis of the genomic regions upstream of OLIG2 ID-1 and ID1transcription start sites revealed the presence of evolutionarily conserved TCF12 binding sites, suggesting that both OLIG2 and ID1 are direct transcriptional targets of TCF12. Taken together, these findings suggest that TCF12 controls the stem-like identity of proneural GSCs by stimulating expression of transcriptional regulators, OLIG2 and ID-1.
MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC
Authors: F. Skoulidis, L. Albacker, M. Hellmann, M. Awad, J. Gainor, M. Goldberg, A. Schrock, L. Gay, J. Elvin, J. Ross, H. Rizvi, B. Carter, J. Erasmus, D. Halpenny, A. Plodkowski, N. Long, M. Nishino-Habatu, W. Denning, J. Rodriguez-Canales, P. Villalobos, E. Parra Cuentas, L. Sholl, J. Sauter, Y. Elamin, J. Zhang, G. Leonardi, K. Wong, P.J. Stephens, V. Papadimitrakopoulou, I. Wistuba, J. Wolchok, A. Shaw, P. Jänne, C. Rudin, V. Miller, J. Heymach
Journal: Journal of Thoracic Oncology (2017)
OA 16.06 Mediastinal Staging by Videomediastinoscopy in Clinical N1 Non-Small Cell Lung Cancer: a Prospective Multicenter Study
Authors: H. Decaluwe, C. Dooms, X. D'Journo, S. Call, D. Sanchez-Lorente, B. Haager, R. Beelen, V. Kara, T. Klikovits, C. Aigner, K. Tournoy, J. Moons, G. Brioude, J.C. Trujillo, B. Bethe, W. Klepetko, A. Turna, B. Passlick, L. Molins, R. Rami-Porta, P. Thomas, P. De Leyn
Journal: Journal of Thoracic Oncology (2017)
P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
Authors: L. Crinò, L. Horn, E. Felip, O. Arén Frontera, M. Burgio, D. Waterhouse, G. Blumenschein, F. Barlesi, M. Garassino, E. Holgado, S. Antonia, D. Spigel, J. Gainor, S. Gettinger, W. Geese, A. Li, D. Healey, N. Ready
Journal: Journal of Thoracic Oncology (2017)
P2.16-019 Improving Survival with a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resections
Authors: N. Faris, M. Smeltzer, C. Fehnel, C. Houston-Harris, P. Ojeabulu, O. Akinbobola, M. Ray, Y. Lee, L. Deese, E. Owen, B. Wolf, H. Wiggins, C. Mutrie, V. Sachdev, P. Levy, R. Signore, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
QLIF-39. BURNOUT AMONG NEURO-ONCOLOGY PROFESSIONALS
Authors: Shlomit Yust-Katz, Barbara J O’Brien, Alvina A Acquaye, Elizabeth Vera, Terri Armstrong
Journal: Neuro-Oncology (2017)

Burnout is a syndrome characterized by emotional exhaustion, depersonalization, and loss of meaning or purpose in work. CNS tumors are highly aggressive tumors with very poor prognosis. Caring for patients with CNS tumors can be challenging, and may place neuro-oncology health care providers at risk for burnout. The goal of this study was to explore the incidence and associated factors for burnout in neuro-oncology health care professionals. A web-based survey of neuro-oncology professionals was conducted between September and December 1, 2016. The survey included the Maslach Burnout Inventory, a 22-item questionnaire considered the gold-standard tool for measuring professional burnout. In addition, questions on demographic, career and lifestyle features were included. 427 neuro-oncology professionals participated in the survey. Participants were primarily female (54%) physicians (72%) practicing in the United States (70%) and a median age between 35-44 years. Although only 32% reported experiencing burnout currently, 63% of participants were identified as having high burnout by the MBI-HS, with basic scientists having the highest overall rate (83%). Remarkably, only 19% reported that their institution had a mechanism in place to address the prevention or support for burnout. More than 70% of physicians reported working more than 50 hours per week, and 95% reported completing work-related tasks at home. Nearly half of participants reported significant stress (7-10 in a scale of 0-10), and did not meet exercise and sleep recommendations for a healthy lifestyle. 55% of respondents considered their income not adequate for the time and effort they devote to their profession. Burnout among neuro-oncology health care providers is a common problem. Estimating the prevalence of burnout and associated risk factors is imperative for improving professional and personal satisfaction and patient care. Implantation of burnout preventive strategies should be considered in the future.
Stopping five low value surgical procedures could save NHS £135m a year
Authors: Susan Mayor
Journal: BMJ (2017)

Stopping five common surgical procedures that are costly and provide limited benefit to patients, including inappropriate gastroscopy and inguinal hernia repair without troublesome symptoms, could save the NHS £135m (€153m; $177m) a year, a study has estimated.1

“Identifying and stopping low value services represents a significantly greater opportunity for efficiency savings than previously thought,” said the researchers, led by Humza Malik, clinical research fellow at Imperial College London, …
NIMG-55. PITUITARY ADENOMAS TREATED WITH FRACTIONATED RADIOTHERAPY: A VOLUMETRIC MRI ANALYSIS
Authors: Vyshak Chandra, Sherry Zhao, Kathryn Workman, Timothy Harris, William Broaddus
Journal: Neuro-Oncology (2017)

Treatment refractory and recurrent pituitary adenomas often require radiation therapy or stereotactic radiosurgery. Long term control with radiation treatment is well known, but the pattern of volume response after radiation has not been characterized in detail. We sought to characterize tumor response to radiation therapy in order to improve clinical decision-making. Patients with biopsy-proven pituitary adenomas were identified from pathology diagnoses at one institution between 2004 and 2014. Inclusion criteria were patients who had received radiation therapy for a pituitary adenoma, who had been followed for a minimum of 3 or more MRI scans, and were over 18 years in age. T1-weighted 3-plane post-contrast MR images were used; tumor dimensions were measured with orthogonal diameters and volumes using the ABC/2 method (simplified ellipsoid volume). In this series, all patients were treated with fractionated radiation therapy. Sixty-one MRI scans for 7 males (44%) and 9 females (66%) were evaluated. Tumor diameters ranged from 0.7cm to 4.22cm. Tumor volumes ranged from 0.12cc to 26.8cc. The median and mean volumes were 3.08cc and 5.25cc, respectively. Follow-up ranged from 8 to 70 months, with a median follow-up of 23 months. Among the 16 tumors that were followed, volumetric analysis showed slopes ranging from -1.75 mm/year to +5.46 mm/year, with a median slope of -0.29 mm/year. 3 tumors showed positives slopes after radiation treatment (18%). Overall survival of this cohort of patients was 100%. Treatment was well tolerated with minimal toxicity. Analysis of scans showed that the majority of tumors respond to fractionated radiation treatment, and our study concludes that this treatment is effective for pituitary adenomas. Future analysis will focus on accurately modeling and predicting tumor volume decay following radiation therapy to aid in clinical decision-making.
NIMG-68. ACCURATE PATIENT-SPECIFIC MACHINE LEARNING MODELS OF GLIOBLASTOMA INVASION USING TRANSFER LEARNING
Authors: Leland Hu, Hyunsoo Yoon, Jennifer Eschbacher, Leslie Baxter, Kris Smith, Peter Nakaji, Samuel Mcgee, Amylou Dueck, Christopher Quarles, John Karis, Andrea Hawkins-Daarud, Pamela Jackson, Susan Massey, Teresa Wu, Kristin Swanson, Jing Li
Journal: Neuro-Oncology (2017)

Contrast-enhanced MRI (CE-MRI) guides first-line therapies (surgery, radiation) for glioblastoma (GBM), yet its accuracy remains limited. CE-MRI delineates enhancing bulk tumor but poorly characterizes non-enhancing invasive tumor in surrounding T2W abnormality. Previous studies have explored advanced MRI to quantify tumor cell density in non-enhancing T2W abnormality, although absence of validation and conflicting results across studies have hindered clinical translation. In this study, we build and cross-validate a predictive model of tumor cell density, using a novel machine-learning (ML) method called transfer-learning (TL) that integrates multi-parametric MRI and spatially-matched biopsies. While conventional ML generalizes models across an entire patient cohort, TL optimizes predictive accuracies in a patient-specific manner. We collected 82 image-guided biopsies from 18 primary GBM patients throughout T1W-enhancing (T1+C) and nonenhancing T2W regions. For each biopsy, we obtained neuropathologist estimates of tumor cell density (0-100%) and spatially matched texture features on multi-parametric MRI (T1+C, T2W, perfusion, diffusion, tensor). Based on this spatially-matched dataset, we developed a TL model that uses texture features to predict tumor cell density. We optimized TL predictive accuracy using leave-one-out-cross-validation (LOOCV) and measured Pearson correlation (r) and mean absolute errors (MAE) of cross-validated predicted tumor cell density vs. true tumor cell density (within +/- 5% range of neuropathology estimates). We compared accuracies against a conventional ML algorithm LASSO (Least-Absolute-Shrinkage-and-Selection-Operator). TL achieved superior correlation compared to LASSO (r=0.89 vs. r=0.51) across all samples (n=82), as well as within non-enhancing samples (n=32) (r=0.90 vs r=0.37). Compared to LASSO, TL dramatically decreased error rates (MAE), with maximal error reduction observed within non-enhancing samples (MAE 24.7% vs 6.8%). We have developed and cross-validated a TL model that improves the accuracy of prediction of tumor cell density within the non-enhancing T2W zone of GBM.
P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
Authors: H. Yu, D. Planchard, J.C. Yang, K.H. Lee, P. Garrido, K. Park, J. Kim, D.H. Lee, S. He, K. Wolff, B. Chao, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2017)